EN DE
STOCK COMPARISON

Sartorius Stedim Biotech vs Intuitive Surgical: Fair Value & Quality

Both stocks run through our valuation models. Here is how Sartorius Stedim Biotech (DIM) and Intuitive Surgical (ISRG) compare, as of Aug 8, 2026.

As of Aug 8, 2026, Fair Value Calculator sees Intuitive Surgical as the less overvalued of the two: Sartorius Stedim Biotech trades at €174 versus a fair value of €51.16 (-71%), while Intuitive Surgical trades at $374 versus $150 (-60%).
Sartorius Stedim Biotech
DIM.PA · EUR · Health Care
-71%
upside to fair value
overvalued
Price€174
Fair Value€51.16
Quality45/100
Intuitive Surgical
ISRG · USD · Health Care
-60%
upside to fair value
overvalued
Price$374
Fair Value$150
Quality56/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Sartorius Stedim BiotechIntuitive Surgical
Valuation
66.2×P/E (TTM)48.3×
6.89×P/S (TTM)13.35×
5.03×P/B7.92×
27.9×EV/EBITDA35.5×
1.61×PEG2.13×
Profitability
9%Net margin28%
20%Operating margin31%
7%Return on equity17%
4%Return on assets10%
Growth
2%Revenue growth (YoY)23%
-5.3%Avg. growth/yr (3Y)17.4%
9.2%Avg. growth/yr (5Y)18.2%
Balance & size
0.46×Debt / equity
$21BMarket cap$141B
mixedGrowth qualityhealthy

Intuitive Surgical leads: 4 to 8 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Sartorius Stedim Biotechof which business quality 50 · market factors 43 Intuitive Surgicalof which business quality 71 · market factors 21
ProfitabilityMargins and returns on capital today
32
66
Quality GrowthAre margins and returns improving?
67
66
CashflowEarnings quality: real cash, not paper profit
50
79
Fin. StrengthBalance sheet, leverage, solvency risk
57
82
InvestmentDisciplined investing over empire-building
21
37
Low VolatilityCalm price path (market factor)
47
39
MomentumPrice trend over the last 3–12 months (market factor)
44
19
52W MomentumDistance to the 52-week high (market factor)
36
4
Net IssuanceBuybacks instead of dilution
70
80

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Sartorius Stedim Biotech

DCF Models€49.42
Earnings-Based€35.00
Dividend Discount€12.14
Multiples€56.57
Asset-Based€28.17
Growth DCF€41.62
Economic Profit€35.28
Growth Earnings€52.09

26 of 26 models see the stock below the current price.

Intuitive Surgical

DCF Models$208
Earnings-Based$160
Dividend Discount$0.40
Multiples$140
Asset-Based$33.72
Growth DCF$176
Economic Profit$105
Growth Earnings$215

25 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Sartorius Stedim Biotech
Bear €33.21Fair Value €51.16Bull €75.07
€174 = current price (white tick)
Intuitive Surgical
Bear $110Fair Value $150Bull $239
$374 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Sartorius Stedim Biotech · Health Care

Quality score45 · below median
Fair value upside-71% · bottom 25%

Intuitive Surgical · Health Care

Quality score56 · above median
Fair value upside-60% · below median

Bottom line

As of Aug 8, 2026, Fair Value Calculator sees Intuitive Surgical as the less overvalued of the two: Sartorius Stedim Biotech trades at €174 versus a fair value of €51.16 (-71%), while Intuitive Surgical trades at $374 versus $150 (-60%).

Intuitive Surgical has the higher quality score (56/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.